Ranibizumab
Treatment for Macular Degeneration
Typical Dosage: 0.5 mg intravitreal injection every 4 weeks, then individualized
Effectiveness
88%
Safety Score
45%
Clinical Trials
381
Participants
60K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mg intravitreal injection every 4 weeks, then individualized
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$16,000
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$17,050
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$18,532.61
Comparison vs Bevacizumab
Cost Difference
+$15,200/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Ranibizumab Outcomes
for Macular Degeneration
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+92%
Common Side Effects
Conjunctival hemorrhage
+15%
Eye pain
+8%
Vitreous floaters
+7%
Increased intraocular pressure
+3%
Endophthalmitis
+0.05%
Retinal detachment
+0.05%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
15 completed trials for Ranibizumab in Macular Degeneration
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
NCT00056836COMPLETEDPHASE3
720 participants
INTERVENTIONAL
Started: Mar 1, 2003
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
NCT00095433COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Started: Sep 1, 2002
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
NCT00061594COMPLETEDPHASE3
426 participants
INTERVENTIONAL
Tucson, United States +81 more
Started: May 1, 2003
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
NCT00090623COMPLETEDPHASE3
180 participants
INTERVENTIONAL
Denver, United States
Started: Aug 1, 2004
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
Chevy Chase, United States +1 more
Started: Aug 1, 2005
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
NCT00056823COMPLETEDPHASE1, PHASE2
168 participants
INTERVENTIONAL
Started: Mar 1, 2003
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01831947COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Göttingen, Germany
Started: Apr 1, 2010
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
NCT02510794COMPLETEDPHASE2
225 participants
INTERVENTIONAL
Mesa, United States +49 more
Started: Sep 28, 2015
Lucentis in Advanced Macular Degeneration
NCT00896779COMPLETEDPHASE2
20 participants
INTERVENTIONAL
San Francisco, United States +1 more
Started: Oct 1, 2009
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
NCT03805100COMPLETEDPHASE3
582 participants
INTERVENTIONAL
Gilbert, United States +101 more
Started: Apr 19, 2019
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
NCT02060604COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Brescia, Italy
Started: Dec 1, 2012
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
NCT02944227COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Seoul, South Korea
Started: Mar 3, 2016
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
NCT00469352COMPLETEDPHASE3
150 participants
INTERVENTIONAL
Portland, United States
Started: May 1, 2007
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
NCT01933152COMPLETED
137 participants
OBSERVATIONAL
Many Locations, Portugal
Started: Aug 1, 2012
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
NCT02420132COMPLETED
47 participants
OBSERVATIONAL
Salt Lake City, United States
Started: Apr 20, 2015
Showing 20 of 384 total trials